uriel-sc-11KDtiUWRq4-unsplash.jpg

Pipeline

We are advancing a pipeline of innovative medicines in four therapeutic areas: Overdose caused by methamphetamine, fentanyl and their co-use; Accidental ADHD medication poisoning in children (Adderall and Ritalin); Reversal of neuromuscular blocking agents in anesthesia; Metabolic and neurodegenerative condition-induced CNS dysfunction. Our pioneering work has produced a first-in-class treatment, CS-1103, for methamphetamine
overdose, a critical public health crisis.

Candidate
In-vivo
POC
NDA
Phase
III

CS-1103

Reduce methamphetamine from the human body to reverse the effect of acute intoxication

Methamphetamine Overdose

cGMP
Manu.
Pre-Clinical
Dev.
IND
Phase
I
Phase
II

CS-1103

Reduce fentanyl from the human body to reverse the effect of acute intoxication

Fentanyl

Overdose

CS-1203

Reversal of overdose caused by co-use of fentanyl and methamphetamine

Overdose From Fentanyl & Methamphetamine Co-use

CS-110x

Reversal of accidental ADHD medication poisoning in children

ADHD Medication Overdose in Children

CS-110y

Reversal Agent for NMBA in Anesthesia

Reversal of the neuromuscular blocking agents in anesthesia

CS-110z

CNS dysfunction caused by metabolic disorders and neurodegenerative diseases

CNS Dysfunction Treatments

Undisclosed

Additional Indications

Additional programs utilizing our novel sequestration platform

Hover for more detail

Clear Scientific has received over $25 million in funding to pursue the development of our pipeline